RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
03. Januar 2023 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer
08. Dezember 2022 06:30 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
30. November 2022 19:05 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused...
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
17. November 2022 21:38 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused...
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
17. November 2022 16:24 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused...
RAPT Therapeutics Reports Third Quarter 2022 Financial Results
10. November 2022 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences
09. November 2022 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires
28. September 2022 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,...
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
31. August 2022 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
11. August 2022 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...